

# 澳大利亚生物技术协会 澳大利亚医疗技术公司名录



## 公司介绍

公司名称: SUDA Ltd

主要联系人姓名: Nick Woolf

主要联系人职务: 首席执行官

公司网址: [www.sudaltd.com.au](http://www.sudaltd.com.au)

公司地址: Level 1, Unit 12, 55 Howe Street, Osborne Park, Perth WA 6017

公司已上市:

## 公司简介

SUDA 有限公司是一家创新型药物传递科技公司, 通过其专利口腔黏膜喷雾技术开发新药物, 提高患者身体健康和生活水平。通过口腔黏膜施药有很多潜在的优势, 包括使用简单, 剂量更小, 副作用更少, 生效时间更短等。

SUDA 产品中进入最终研发阶段的舌下蒿甲醚喷雾 (ArTiMist™), 属款同类首发, 用于治疗儿童疟疾。ArTiMist™ 已显示出更稳定的施药剂量反应并且避免了口服青蒿素类单一疗法会带来首过反应。公司目前已经成功的完成了 ArTiMist™ 对儿童重度疟疾的临床测试, 正在准备向监管机构递交申请。

SUDA 也对 300 多种常用药物的活性成分制成口腔黏液喷雾有专利保护。本公司的开发产品中包括用于治疗偏头痛的舒马曲坦口腔喷雾 (SUD-001); 抗化疗引发的恶心和呕吐的恩丹西酮口腔喷雾 (SUD-002); 抗勃起功能障碍的西地那非 (SUD-003) 及 PAH (SUD-004) 口腔喷雾; 和抗焦虑的咪达唑仑 (SUD-005) 口腔喷雾。

SUDA 的策略是将这些产品商业化并通过向外出租许可和共同开发合作来扩大其产品线。

## 关键技术或领先技术

SUDA OroMist 口腔黏膜技术可以通过脸颊、牙龈、舌头或舌下送达种类繁多的药物。该技术适于, 并且已经注册专利保护, 使用泵 (气体激发) 或气溶胶 (压缩气器) 喷雾系统。可以基于医疗需要和市场需求为每个产品提供多种不同剂量的产品。

对比其他送药方式，这项技术和给药途径可带来多种实在的优势：

- 缩短药物的生效时间
- 降低用药剂量
- 避免首先被肝脏分解，提高生物药效率
- 最大限度地减少由于肠胃蠕动引起的剂量变化
- 提高患者的配合度和方便性
- 无需吞咽。为众多有吞咽困难的患者避免这一难题。
- 患者用药时无需用水
- 帮助自我服药
- 降低对医疗人员的需求

通过口腔黏膜送药可以最大限度的减少由于肠胃蠕动、胃部排空的时间、食物的作用、片剂 / 胶囊瓦解和溶出和酶解或在肠道内进行化学降解引起的剂量变化。由于分解更少，吸收更好，和同种药物片剂配方相比，口腔喷剂通常可使用更小剂量的活性成分。有可能会减轻用药不良反应发生的风险。

在许多情况下，比如在治疗吞咽困难和有恶心问题的患者，使用口腔喷剂用药，患者会更好地配合。

### 类别

设备类：口腔黏膜喷雾施药器械组合

### 关键或领先技术的发展阶段

临床试验阶段

### 合作机会

SUDA 在寻求有兴趣共同开发并将口腔黏膜喷雾技术商业化的医药公司进行合作。

---

# Directory of Australian medtech companies



## **COMPANY DETAILS**

**Company name:** SUDA Ltd

**Key contact name:** Nick Woolf

**Job title of key contact:** Chief Business Officer

**Company website address:** [www.sudaltd.com.au](http://www.sudaltd.com.au)

**Company address:** Level 1, Unit 12, 55 Howe Street, Osborne Park, Perth WA 6017

**The company is Listed.**

## **ABOUT THE COMPANY**

SUDA Ltd is a drug delivery company utilising proprietary oro-mucosal spray technology to develop innovative pharmaceuticals that improve the health and lifestyle of patients. The many potential benefits of administering drugs through the oral mucosa include ease of use, lower dosage, reduced side effects and faster response time.

SUDA's most advanced development-stage product is a first-in-class sub-lingual spray of artemether (ArTiMist™) for treatment of malaria in children.. ArTiMist™ has shown a more consistent dose response and avoids the first pass effect associated with oral artemisinin-based monotherapies. ArTiMist™ has successfully completed a Phase III trial in severe paediatric malaria and the Company is preparing a regulatory submission.

SUDA has IP covering over 300 widely-used APIs formulated into oro-mucosal sprays. The Company's development pipeline also includes oral sprays of sumatriptan for migraine (SUD-001); ondansetron for chemo-induced nausea and vomiting (SUD-002); sildenafil for erectile dysfunction (SUD-003) and PAH (SUD-004); and midazolam for anxiety (SUD-005).

SUDA's strategy is to commercialise its products and expand its pipeline through out-licensing and collaborative development.

## **KEY OR LEAD TECHNOLOGY**

SUDA's OroMist oro-mucosal technology can deliver a broad range of drug classes through either the cheeks, gums, tongue or floor of the mouth. The technology is compatible with, and patented for, use in either pump (air-activated) or aerosol (propellant-driven) spray systems, and can be provided in either multi-dose or unit containers based on the medical need and marketing requirements for each product.

The technology and delivery route can provide meaningful benefits compared to other modes of drug administration, including:

- provide faster onset of action;
- reduce the dose level;
- increase bioavailability of the drug by avoiding first pass metabolism in the liver
- minimise dose variation related to gastrointestinal tract motility;
- enhance patient compliance and convenience;
- avoid the need to swallow, which is a problem for many people;
- allow for the medication to be taken without water;
- facilitate self-medication; and
- decrease the need of medical personnel.

Drug delivery via the oral mucosa can minimise dose variation related to gastrointestinal tract motility, stomach emptying time, food effects, tablet/capsule disintegration and dissolution and enzymatic or chemical degradation in the gut. Due to decreased degradation and higher absorption, oral sprays often permit the use of a lower dose of the active ingredient compared with tablet formulations of the same drug, potentially reducing the risk of adverse drug reactions.

In many cases, including treatments for patients with difficulty swallowing or nausea, oral spray administration provides enhanced convenience resulting in greater compliance.

### **Category**

**Devices:** Drug-device combinations for delivery via an oro-mucosal spray

### **Point of development of key or lead technology**

In clinical trials

### **OPPORTUNITIES SOUGHT**

SUDA is seeking to collaborate with pharmaceutical companies that are interested in developing and commercialising oro-mucosal sprays.